Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Marpai, Inc. (MRAI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Marpai’s filings describe its business as a technology platform company operating subsidiaries that provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. Its Class A common stock is listed on the OTCQX Market under the symbol MRAI.
Through periodic and current reports, Marpai presents financial statements, details of its operating performance and information about its capital structure. For example, Form 8-K filings included in this record describe private placements of Class A common stock and warrants under Securities Purchase Agreements, with proceeds intended for working capital and general corporate purposes. Other 8-K filings reference amendments to the company’s certificate of incorporation, such as the authorization of blank-check preferred stock, and the release of selected financial information for specific reporting periods.
Annual proxy materials, such as the definitive proxy statement (DEF 14A), outline governance matters, including the election of directors, ratification of the independent registered public accounting firm and proposals to amend the certificate of incorporation. These documents also confirm key facts such as Marpai’s Delaware incorporation, its Tampa, Florida office location and the voting rights associated with its Class A common stock.
On this page, users can review Marpai’s Forms 10-K and 10-Q (when available), current reports on Form 8-K, proxy statements and other filings. Stock Titan’s tools can surface summaries and key points from longer documents, helping readers understand topics such as equity issuances, changes to the capital structure, governance proposals and how Marpai presents its TPA and PBM operations in official filings.
SHIV SAGIV reported acquisition or exercise transactions in this Form 4 filing.
Marpai, Inc. director Shiv Sagiv received an equity grant of 100,000 shares of Class A Common Stock in the form of restricted stock units. The grant price is shown as $0.00 per share, indicating compensation rather than an open-market purchase.
According to the vesting terms, one-third of these RSUs vested on February 19, 2026, one-third vests upon execution of a Board-approved letter of intent or comparable indication of interest for a potential strategic transaction, and the final third vests upon the closing of that strategic transaction, in each case requiring continued service. After this award, Sagiv directly holds 522,000 shares of Marpai, Inc. common stock.
Marpai, Inc. files its annual report describing a technology-driven third-party administrator and pharmacy benefit manager serving self-insured employers in the U.S. The company emphasizes AI‑enabled cost containment, care management and pharmacy savings programs, operating with 107 full-time employees as of December 31, 2025.
Marpai reports substantial financial strain: an accumulated deficit of $115.4 million, negative working capital of $15.4 million, short-term debt of $11.0 million, long-term debt of $17.2 million and only $133 thousand of unrestricted cash as of December 31, 2025, alongside a $16.6 million net loss and $7.5 million negative operating cash flow for 2025.
Management and the independent auditor conclude these conditions raise substantial doubt about Marpai’s ability to continue as a going concern, and the company expects to need additional debt or equity financing or asset sales, which could significantly dilute existing stockholders. The filing also highlights a high client attrition rate of approximately 28% in 2025, customer concentration, intense competition, regulatory and cybersecurity risks, and notes that Marpai’s common stock has been delisted from Nasdaq and now trades on the OTCQX, is considered a penny stock, and may be harder for investors to trade.
Marpai, Inc. entered into a short-term financing arrangement with its Chief Executive Officer. On March 9, 2026, the company issued a $250,000 promissory note to CEO Damien Lamendola at an annual interest rate of 12.0%. The note is repayable, together with accrued interest and any other amounts due, by May 10, 2026 and can be prepaid at any time without penalty. Marpai plans to use the proceeds for general working capital needs, providing near-term liquidity funded directly by its chief executive.
Marpai, Inc. files an Amendment to Schedule 13G/A reporting beneficial ownership. The amendment states that Intelligent Fanatics Capital Management LLC, IFCM MicroCap Fund LP and Ian J. Cassel each have beneficial ownership of 1,030,085 common shares, representing 4.4% of the class as reported in the filing.
The filing shows shared voting and dispositive power of 1,030,085 shares for each reporting person and includes a statement that the Fund holds the securities directly while Mr. Cassel disclaims direct beneficial ownership except for partnership interests.
Marpai, Inc. entered into a related-party financing arrangement by issuing a promissory note for $410,000 to its Chief Executive Officer, Damien Lamendola. The note carries 12.0% annual interest and may be prepaid at any time without penalty. All principal, interest, and other amounts are due by April 11, 2026. Marpai plans to use the proceeds for general working capital needs, providing short-term liquidity funded directly by its CEO.
Marpai, Inc. reported that President Dallas Scrip resigned from his position, effective January 30, 2026. The company stated that his resignation was not due to any disagreement regarding operations, policies, or practices.
As a result, the Board appointed current Chief Executive Officer Damien Lamendola, age 70, to also serve as President effective the same date, consolidating both roles under one executive. He has been CEO since November 2023 and has served on the Board since April 2021.
The filing notes Mr. Lamendola’s prior and ongoing leadership roles at various affiliated entities and references several securities purchase agreements between Marpai, entities controlled by him, and an immediate family member, with the material terms previously disclosed and incorporated by reference. Aside from those transactions and his existing compensation, the company states there are no additional related-party transactions reportable under Item 404(a) or arrangements leading to his appointment.
Marpai, Inc. received a Schedule 13G/A filing from Intelligent Fanatics Capital Management LLC, IFCM MicroCap Fund LP, and Ian Cassel reporting a significant ownership stake. The filing states that IFCM MicroCap Fund LP beneficially owns 1,325,636 common shares, representing 5.6% of Marpai’s common stock. Intelligent Fanatics Capital Management LLC, as general partner of the fund, and Ian Cassel, as the sole managing member of IFCM, each report shared voting and shared dispositive power over these 1,325,636 shares and no sole voting or dispositive power.
The filing explains that the securities are held directly by IFCM MicroCap Fund LP and that Mr. Cassel may be deemed a beneficial owner through his interests in the fund, while he disclaims beneficial ownership beyond his economic interest. The reporting persons certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Marpai.
Marpai, Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors to raise approximately $350,000 in a private placement. The Company agreed to issue and sell 350,000 shares of Class A common stock together with warrants to purchase up to 700,000 additional shares of common stock, at a combined purchase price of $1.00 per share and accompanying warrant.
The common warrants have an exercise price of $1.00 per share, are exercisable immediately after closing, and remain exercisable for three years from issuance, with customary anti-dilution provisions. Marpai plans to use the proceeds for working capital and general corporate purposes, and granted investors a six‑month right to include the shares and warrant shares in any other registration of securities it files, subject to limited exceptions.
Marpai, Inc. reported Q3 results and flagged substantial doubt about its ability to continue as a going concern. Revenue was $4.037 million, down 42% year over year, as customer turnover reduced volumes. The quarter’s net loss was $3.494 million, with interest expense of $797 thousand reflecting higher-cost debt.
At September 30, 2025, cash and cash equivalents were $445 thousand against total liabilities of $46.099 million and a stockholders’ deficit of $33.346 million. Working capital was negative $10.7 million. Convertible debentures had a net carrying amount of $9.840 million bearing 14% interest with $250 thousand monthly principal payments; liabilities due to AXA totaled $18.952 million due by December 31, 2028.
Year to date, revenue was $14.111 million (down 34.6%) and operating loss improved to $8.627 million due to cost reductions across G&A, facilities, and depreciation. Management is exploring strategic alternatives and raised capital through several private placements. The company disclosed ongoing litigation relating to a lease subtenant dispute.
Marpai, Inc. (MRAI) filed a current report announcing it issued a press release with selected financial information for the three and nine months ended September 30, 2025. The release is provided as Exhibit 99.1.
The filing identifies the company’s Class A common stock trading on the OTCQX Market under the symbol MRAI. No additional operational or financial details are included in this report beyond the exhibit reference.